The experience of chemotherapy for lung cancer show promising potential
The experience of therapeutic Japan using a real estate chemotherapy experimenters for the treatment of cancerous tumors is different, they are together a promising alternative to conventional therapy or standard of cases of advanced lung cancer, according to sources with the American Association for Cancer Research, published the outcome of the experiment patrol duty, "Cancer Research, Clinical."
The experiment was performed several treatment centers, and in the second phase took part in the trial of 56 patients with advanced cases of lung cancer is common.
The results of the experiment using a real estate S-1 and Irenotikan in terms of level of response, and the continuation of the lives of patients without worsening of cancer, and overall survival, similar to or better than those reported from standard treatment with platinum-based chemotherapy.
Toxicity of platinum therapy
Because they are single-track experience, as all patients received the experimental treatment, without a comparison group dealing with standard chemotherapy, the researchers can not directly compare the benefits of both methods of treatment.
However, they did not mention whether the experimental treatment side effects less severe than those usually caused by standard treatment. It seems that patients and their doctors rejecting the toxicity of chemotherapy platinum standard, due to lack of interest in the survival of patients, which reinforces the need for effective treatments less toxic effects.
Says study author and professor of Oncology, Faculty of Medicine University of kinky in Osaka, Japan Isamu Okamoto should conduct a remedial "dual track" for a direct comparison between the experimental treatment and standard treatment to ascertain any benefits relating to prolong the survival of patients in the use of real estate S-1 and Irenotikan.
Three mechanisms of action
The drug S-1 is approved for use in Japan and Korea, where it has shown substantial benefit in treating gastric cancer, but it is still in clinical trials in other countries, such as Europe and the United States.
The multifaceted agent, which is available in capsule form, has three different mechanisms. One part breaks down into active fluorouracil (5-FU), once in the body. Alvrurassel and a chemotherapy drug often used to treat cancers of the colon and rectum, and others.
Another part of the drug S-1-FU continues to produce a steady level, while the third part is designed to address the FU's toxic effects, such as nausea and vomiting.
The Irenotikan an intravenous drug, was originally developed and tested in Japan, and approved in the United States in 1994, and is often used to treat colon cancer. And is currently used in Japan to treat lung cancer, but not so used in other countries.
The level of response and survival
Japanese researchers believe that the combination of real estate S-1 and provides Irenotikan impact of solidarity. When tested as S-1 first-line chemotherapy for advanced lung cancer, the response rate was 22%, with survival time of 10.2 months.
For the completion of the study, enrolled in this trial patients with advanced lung cancer did not receive any treatment, in 14 centers in Japan, where they received an average of five cycles of treatment. The response rate was 28%, and the median survival without a worsening of cancer about five months, and median overall survival was 15 months.
See Okamoto These results compare favorably with the results of testing a dual-track chemotherapy platinum, which demonstrated response rates of 17 to 33%, a median survival periods without worsening of cancer cases between three and five months and median overall survival time of seven to 14 months.
The researcher confirms that this experimental therapy is a promising alternative, but needs further testing in randomized trials, two-way.
0 commentaires